Providers Flex Clout for Product Identification Standards
Executive Summary
The push for more efficient, cost effective ways to provide health care is a never-ending vigil filled with inherent complications and obstacles to success. However, on close examination, it becomes apparent it is not for lack of good ideas and techniques that improvement efforts are hampered, but rather a lack of uniform clout to force the wide assortment of vested players to come together and agree on a single solution. This has been a chief impediment in preventing the health care supply chain from realizing a standardized product identification system--until now.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.